RxDoctor Payments Data
★ My doctorsLook up a doctor →

Lisa-Gaye Giscombe, MD

Hematology & Oncology · Miami, FLNPI 1891113189

Payments from drug & device makers

$10,805in general payments, 2019–2025

Across 423 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Pfizer$784
  • Merck$783
  • Exelixis Inc.$608
  • Bristol Myers Squibb$481
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,60389%
  • Education$1,20311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)39$1,391
AstraZeneca(2 entities)38$1,047
Pfizer40$784
Merck35$783
Exelixis Inc.21$608
Bristol Myers Squibb22$481
Eisai Inc.12$375
Incyte Corporation11$338
Novartis14$300
Bayer12$294
Daiichi Sankyo Inc.9$292
Sobi, Inc7$274
AbbVie11$243
GSK10$227
Genentech USA, Inc.7$193
Array Biopharma Inc9$192
Seagen Inc.5$190
Pharmacosmos Therapeutics Inc.8$185
Lilly USA, LLC6$142
E.r. Squibb & Sons, L.L.C.7$141
Tempus AI, Inc5$129
Servier Pharmaceuticals LLC5$129
Adaptive Biotechnologies Corporation5$125
Sanofi4$105
Karyopharm Therapeutics Inc.4$104
AVEO Pharmaceuticals, Inc.3$102
EMD Serono, Inc.5$91
Astellas Pharma US Inc4$81
Boehringer Ingelheim3$79
ADC Therapeutics America, Inc.3$79
Beigene USA, Inc.4$78
Myriad Genetic Laboratories, Inc.3$74
Takeda Pharmaceuticals U.S.A., Inc.3$72
Caris MPI, Inc.3$70
Stemline Therapeutics Inc.3$68
Legend Biotech USA Inc.2$64
Beone Medicines USA, Inc.2$55
Ipsen Biopharmaceuticals, Inc2$52
Agios Pharmaceuticals, Inc.2$46
Gilead2$44
G1 Therapeutics, Inc.2$43
Puma Biotechnology, Inc.2$41
Genmab U.S., Inc.2$40
Taiho Oncology, Inc.2$40
Foundation Medicine, Inc.2$36
Deciphera Pharmaceuticals Inc.1$33
Azurity Pharmaceuticals, Inc.2$32
Regeneron Healthcare Solutions, Inc.1$30
Organon2$30
Rigel Pharmaceuticals, Inc.1$29
Blueprint Medicines Corporation1$28
GE HealthCare1$26
Novocure Inc.1$25
Mirati Therapeutics, Inc.1$24
Morphosys, US Inc.1$23
Spectrum Pharmaceuticals Inc.1$23
Menarini Silicon Biosystems, Inc.1$21
Octapharma USA, Inc.1$20
Cumberland Pharmaceuticals, Inc.1$19
Jazz Pharmaceuticals Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,805 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$7,953
Medicare patients
18
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →